Developing small peptides to neutralize SARS-CoV-2 variants
Broadly neutralizing SARS-CoV-2 peptidic knobs
This study is exploring new tiny proteins made from cow antibodies that could help fight the COVID-19 virus and its variants, and they might be given in different ways, like through inhalation, to help keep you safe and healthy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Applied Biomedical Science Institute NIH-funded |
| Lab location | 1 site (San Diego, United States) |
| Project ID | NIH-11097381 on NIH RePORTER |
What this research studies
This research focuses on creating small, stable peptides that can effectively neutralize the SARS-CoV-2 virus, including its variants like delta and omicron. By utilizing peptides derived from unique cow antibodies, the team aims to produce these molecules in a way that retains their high binding affinity and potency against the virus. The peptides are designed to be administered through various routes, potentially including inhalation, making them a versatile option for both treatment and prevention of COVID-19. Patients may benefit from these innovative therapies that could provide a new way to combat the virus.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk of COVID-19 infection, including those with underlying health conditions or those exposed to the virus.
Not a fit: Patients who are not at risk for COVID-19 or those who have already been vaccinated may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to new, effective treatments for COVID-19 that are easy to administer and highly potent against multiple variants.
How similar studies have performed: Other research has shown promise in using peptide-based therapies for viral neutralization, indicating potential success for this novel approach.
Where this research is happening
San Diego, United States
- Applied Biomedical Science Institute — San Diego, United States (Active)
Researchers
- Principal investigator: Smider, Vaughn Vasil — Applied Biomedical Science Institute
- Study coordinator: Smider, Vaughn Vasil
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.